Greiner Bio-One GmbH, Baden-Wrttemberg, Germany), at a density of 0.8 10 4 cells/cm 2 and cultured in DMEM-F12 for three days
J Biol Chem 275:1325913265 Brandsma D, Kerklaan BM, Diras V, Altintas S, Anders CK, Ballester MA, Gelderblom H, Soetekouw PMMB, Gladdines W, Lonnqvist F et al (2014) Phase 1/2a study of glutathione pegylated liposomal doxorubicin (2b3-101) in patients with brain metastases (BM) from solid tumors or recurrent high grade gliomas (HGG)
There was a B association between smokers whose OR was 0.81 with a 95% confidence interval between 0.73 and 0.90) and non-smokers whose OR was 0.97 and whose 95% confidence interval was between 0.93 and 1.02
For clinicians and patients, the practical timeline matters: CagriSema is closer to potential approval (phase 3 complete), while amycretin's phase 3 is planned for 2026